REQUEST FOR INFORMATION
Use the form below to submit your request for information to Altasciences.
...working with Altasciences has been excellent, from both a bioanalytical, and a bioavailability study perspective. We are really impressed with their planning and execution abilities – I would not consider another provider for future work.
Watch the Video
Focused on your needs, our specialists provide appropriate support for precision bioanalysis, and a full range of research services for a wide range of study types — working with you to accelerate development, meet your milestones, and ensure compliant, on-time regulatory submissions for your drug candidates.
Related Press Release
Mar 27, 2020
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
As part of our full service offering or as standalone solutions
From formulation development, phase I through commercial manufacturing, and ICH stability testing
We have received your message and will contact you shortly.